Drug Profile
BMS 986263
Alternative Names: BMS-986263; ND-L02-s0201Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Nitto Denko
- Developer Bristol-Myers Squibb; Nitto Denko
- Class Antifibrotics; Hepatoprotectants; Small interfering RNA
- Mechanism of Action HSP47 heat shock protein expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis; Liver cirrhosis
- No development reported Fibrosis; Hepatic fibrosis
Most Recent Events
- 09 Feb 2024 Bristol-Myers Squibb terminates a phase II trial in Liver cirrhosis in United Kingdom, Taiwan, Switzerland, Spain, Puerto Rico, South Korea, Japan, Italy, Israel, France, Canada, Brazil, Belgium, Argentina, USA (IV), due to lack of efficacy in the short term acute phase (NCT04267393)
- 02 Jan 2023 BMS 986263 is still in phase II trials for Idiopathic-pulmonary-fibrosis in USA, Germany, Japan and UK (NCT03538301)
- 02 Jan 2023 BMS 986263 is still in phase II trials for Liver cirrhosis in Germany (IV, Infusion) (NCT03420768)